Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 183

Results For "Clinical"

3391 News Found

Dr. Reddy's Laboratories acquires Preferred A-1 shares of Edity Therapeutics
News | December 30, 2023

Dr. Reddy's Laboratories acquires Preferred A-1 shares of Edity Therapeutics

The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares


Innovent and SanegeneBio collaborate to develop siRNA drug for treatment of hypertension
Clinical Trials | December 28, 2023

Innovent and SanegeneBio collaborate to develop siRNA drug for treatment of hypertension

Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908


Elpiscience and Astellas collaborate for novel bispecific macrophage engager
News | December 28, 2023

Elpiscience and Astellas collaborate for novel bispecific macrophage engager

Elpiscience will receive up to US $37 million, including the upfront payment and license option fees


Mandaviya virtually launches 'MedTech Mitra'
Policy | December 27, 2023

Mandaviya virtually launches 'MedTech Mitra'

MedTech Mitra is a platform that will help the young talents of the country by holding their hands and giving them final shape to their research, knowledge and logic


AstraZeneca to acquire China's Gracell Biotechnologies for US $1.2 billion
News | December 26, 2023

AstraZeneca to acquire China's Gracell Biotechnologies for US $1.2 billion

Furthering cell therapy ambition across oncology and autoimmune diseases


Roche receives USFDA’s priority review to Xolair for food allergies based on positive NIH Phase III study results
Drug Approval | December 26, 2023

Roche receives USFDA’s priority review to Xolair for food allergies based on positive NIH Phase III study results

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure


BioVaxys executes LoI for major Immunotherapeutics technology acquisition
News | December 26, 2023

BioVaxys executes LoI for major Immunotherapeutics technology acquisition

BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement


Astellas completes acquisition of Propella Therapeutics
News | December 26, 2023

Astellas completes acquisition of Propella Therapeutics

Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer


Lyndra Therapeutics raises US$101 million in Series E funding
News | December 25, 2023

Lyndra Therapeutics raises US$101 million in Series E funding

Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners


USFDA grants priority review for Patritumab Deruxtecan in US for certain patients with EGFR-mutated non-small cell lung cancer
Drug Approval | December 23, 2023

USFDA grants priority review for Patritumab Deruxtecan in US for certain patients with EGFR-mutated non-small cell lung cancer

If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients